Apparent differences in mechanisms of harmol sulfate biliary excretion in mice and rats

Drug Metabolism and Disposition

Volumn 36, Issue 11, 2008, Pages 2156-2158

  Zamek Gliszczynski, Maciej J ^a,b   Hoffmaster, Keith A ^a,c   Nezasa, Ken Ichi ^a,d   Brouwer, Kim L R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; ELACRIDAR; GLYCOPROTEIN P; HARMOL; HARMOL SULFATE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG EXCRETION; DRUG TRANSPORT; ISOLATED LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE;

ACRIDINES; ANIMALS; BILIARY TRACT; HARMINE; LIVER; MALE; MICE; MICE, INBRED C57BL; RATS; RATS, WISTAR; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROISOQUINOLINES;

MUS; RATTUS; RATTUS NORVEGICUS;

EID: 54349127577     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.022053     Document Type: Article

References (14)

1. de Bruin M, Miyake K, Litman T, Robey R, and Bates SE (1999) Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 146:117-126.
2. de Vries MH, Groothuis GM, Mulder GJ, Nguyen H, and Meijer DK (1985) Secretion of the organic anion harmol sulfate from liver into blood. Evidence for a carrier-mediated mechanism. Biochem Pharmacol 34:2129-2135.
3. Funk C, Ponelle C, Scheuermann G, and Pantze M (2001) Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 59:627-635.
4. Gregus Z, Madhu C, and Klaassen CD (1988) Species variation in toxication and detoxication of acetaminophen in vivo: a comparative study of biliary and urinary excretion of acetaminophen metabolites. J Pharmacol Exp Ther 244:91-99.
5. Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, and Brouwer KL (2004) Hepatobiliary disposition of the metabolically stable opioid peptide [D-penicillamine2,5]enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems. J Pharmacol Exp Ther 311:1203-1210.
6. Kostrubsky VE, Vore M, Kindt E, Burliegh J, Rogers K, Peter G, Altrogge D, and Sinz MW (2001) The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats. Drug Metab Dispos 29:1561-1566.
7. Mulder GJ and Bleeker B (1975) UDP glucuronyltransferase and phenolsulfotransferase from rat liver in vivo and in vitro-IV. Species differences in harmol conjugation and elimination in bile and urine in vivo. Biochem Pharmacol 24:1481-1484.
8. Pang KS, Schwab AJ, Goresky CA, and Chiba M (1994) Transport, binding, and metabolism of sulfate conjugates in the liver. Chem Biol Interact 92:179-207.
9. Pang KS and Terrell JA (1981) Retrograde perfusion to probe the heterogeneous distribution of hepatic drug metabolizing enzymes in rats. J Pharmacol Exp Ther 216:339-346.
10. Suzuki M, Suzuki H, Sugimoto Y, and Sugiyama Y (2003) ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 278:22644-22649.
11. Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, Tian X, Nezasa K, and Brouwer KLR (2006a) Differential involvement of Mrp2 (Abcc2) and Bcrp1 (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J Pharmacol Exp Ther 319:459-467.
12. Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Tallman MN, and Brouwer KLR (2006b) Integration of hepatic drug transporters and phase II metabolizing enymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci 27:447-486.
13. Zamek-Gliszczynski MJ, Nezasa K, Tian X, Kalvass JC, Patel NJ, Raub TJ, and Brouwer KLR (2006c) The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol Pharmacol 70:2127-2133.
14. Zelcer N, van de Wetering K, Hillebrand M, Sarton E, Kuil A, Wielinga PR, Tephly T, Dahan A, Beijnen JH, and Borst P (2005) Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci U S A 102:7274-7279.